000 -LEADER |
fixed length control field |
03485nam a22004575i 4500 |
001 - CONTROL NUMBER |
control field |
978-1-59745-274-8 |
003 - CONTROL NUMBER IDENTIFIER |
control field |
DE-He213 |
005 - DATE AND TIME OF LATEST TRANSACTION |
control field |
20161121230803.0 |
007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION |
fixed length control field |
cr nn 008mamaa |
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
fixed length control field |
100301s2008 xxu| s |||| 0|eng d |
020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
International Standard Book Number |
9781597452748 |
-- |
978-1-59745-274-8 |
024 7# - OTHER STANDARD IDENTIFIER |
Standard number or code |
10.1007/978-1-59745-274-8 |
Source of number or code |
doi |
050 #4 - LIBRARY OF CONGRESS CALL NUMBER |
Classification number |
RC261-271 |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MJCL |
Source |
bicssc |
072 #7 - SUBJECT CATEGORY CODE |
Subject category code |
MED062000 |
Source |
bisacsh |
082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
Classification number |
614.5999 |
Edition number |
23 |
245 10 - TITLE STATEMENT |
Title |
Checkpoint Responses in Cancer Therapy |
Medium |
[electronic resource] / |
Statement of responsibility, etc. |
edited by Wei Dai. |
264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE |
Place of production, publication, distribution, manufacture |
Totowa, NJ : |
Name of producer, publisher, distributor, manufacturer |
Humana Press, |
Date of production, publication, distribution, manufacture, or copyright notice |
2008. |
300 ## - PHYSICAL DESCRIPTION |
Extent |
XIV, 314 p. 33 illus., 3 illus. in color. |
Other physical details |
online resource. |
336 ## - CONTENT TYPE |
Content type term |
text |
Content type code |
txt |
Source |
rdacontent |
337 ## - MEDIA TYPE |
Media type term |
computer |
Media type code |
c |
Source |
rdamedia |
338 ## - CARRIER TYPE |
Carrier type term |
online resource |
Carrier type code |
cr |
Source |
rdacarrier |
347 ## - DIGITAL FILE CHARACTERISTICS |
File type |
text file |
Encoding format |
PDF |
Source |
rda |
490 1# - SERIES STATEMENT |
Series statement |
Cancer Drug Discovery and Development• |
505 0# - FORMATTED CONTENTS NOTE |
Formatted contents note |
RB-Pathway -- Targeting the p53/MDM2 Pathway for Cancer Therapy -- DNA Topoisomerases as Targets for the Chemotherapeutic Treatment of Cancer -- Targeting ATM/ATR in the DNA Damage Checkpoint -- Compounds that Abrogate the G2 Checkpoint -- CDK Inhibitors as Anticancer Agents -- CHFR as a Potential Anticancer Target -- Antimicrotubule Agents -- Kinesin Motor Inhibitors as Effective Anticancer Drugs -- Targeting the Spindle Checkpoint in Cancer Chemotherapy -- Antiproliferation Inhibitors Targeting Aurora Kinases -- Plks as Novel Targets for Cancer Drug Design -- Do Histone Deacetylase Inhibitors Target Cell Cycle Checkpoints that Monitor Heterochromatin Structure?. |
520 ## - SUMMARY, ETC. |
Summary, etc. |
Extensive research has uncovered a set of molecular surveillance mechanisms – commonly called "checkpoints" – which tightly monitor cell-cycle processes. Today’s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book’s distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Medicine. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cancer research. |
650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Pharmacology. |
650 14 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Biomedicine. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Cancer Research. |
650 24 - SUBJECT ADDED ENTRY--TOPICAL TERM |
Topical term or geographic name entry element |
Pharmacology/Toxicology. |
700 1# - ADDED ENTRY--PERSONAL NAME |
Personal name |
Dai, Wei. |
Relator term |
editor. |
710 2# - ADDED ENTRY--CORPORATE NAME |
Corporate name or jurisdiction name as entry element |
SpringerLink (Online service) |
773 0# - HOST ITEM ENTRY |
Title |
Springer eBooks |
776 08 - ADDITIONAL PHYSICAL FORM ENTRY |
Relationship information |
Printed edition: |
International Standard Book Number |
9781588299307 |
830 #0 - SERIES ADDED ENTRY--UNIFORM TITLE |
Uniform title |
Cancer Drug Discovery and Development• |
856 40 - ELECTRONIC LOCATION AND ACCESS |
Uniform Resource Identifier |
http://dx.doi.org/10.1007/978-1-59745-274-8 |
912 ## - |
-- |
ZDB-2-SBL |